Dementia Drugs Market (By Drug Class: MAO Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors; By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Others) - Global Industry Analysis, Market Size, Opportunities And Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190

The global dementia drugs market is anticipated to grow at a CAGR of around 8.5% during the forecast period 2020 to 2027 and to reach around US$ 24.7 Bn by 2027.

Market Dynamics

Increasing number of patients suffering from chronic diseases, high government spending on drug development and major players focus on introduction of innovative solutions are major factors expected to drive the growth of global dementia drugs market.

According to Alzheimer’s Association, approximately 5.7 million people were living with dementia in 2018 within the United States. In addition, they projected that 13.9 million individuals aged 65 years or older will be diagnosed with Alzheimer’s disease or related dementias in the United States by 2060. According to World Health Organization worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. In addition, government is spending high for developing the healthcare infrastructure in order to support the R&D activities along with availability of various business policies is influencing the growth of target market. Players focus on enhancing the business presence in developing countries in order to enhance the business presence is expected to augment the growth of target market. In addition, focus on enhancing the business presence through strategic partnerships and product launches is expected to support the growth of target market.

In 2019, the FDA approved Rivastigmine (Exelon®), for mild-to-moderate Alzheimer’s as well as mild to moderate dementia associated with Parkinson’s disease.

In 2019, Biogen a global drug company submitted the application to Food and Drug Administration to approve an experimental drug, aducanumab, to treat people with mild cognitive impairment and the earliest signs of Alzheimer’s disease.

In 2016, Ajanta Pharma Limited launched anti-dementia Memantine Hydrochloride tablets in the US market. This is expected to help the company to enhance the customer base and strengthen its position in US market.

Initiatives by the government and non-government agencies to establish a platform with the focus to treat the patients suffering from dementia are increasing. In 2017 World Health Organization, established Global Dementia Observatory, an international surveillance platform for policy-makers and researchers to facilitate monitoring and sharing of information on dementia policies, service delivery, epidemiology and research.

However, factors such as high cost associated to R&D activities and stringent government regulations related to product approval are factors expected to hamper the growth of global dementia drugs market. In addition, lack of regulatory standards in developing country is expected to challenge the growth of target market.

High investment by the government for drug development, rapid technological advancements in drug discovery technique, and players approach towards introduction of innovative solutions are factors expected to create new opportunities for players operating in the target market. In addition, increasing partnership between regional and international players is expected to support the revenue growth of target market.

Segment Analysis by Region

The market in North America is expected to account for significant revenue share owing to increasing number of patients suffering from chronic diseases. In addition, availability of advanced healthcare infrastructure and high investment by players for R&D activities are factors expected to support the growth of target market.

Increasing focus on merger and acquisition activities in order to increase the business profit ratio and enhance the product portfolio is expected to support the growth of target market.

Competitive Landscape                                                                                 

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Market

Global Dementia Drugs Market

Analysis Period

2016 – 2027

Base Year

2019

Forecast Data

2020 – 2027

Market Stratification

Drug Class, Distribution Channel and Geography

Regional Scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Report Coverage

Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis


Dementia Drugs Market Segment Analysis, 2019

The global dementia drugs market is segmented into drug class and distribution channel. The drug class is segmented into MAO inhibitors, glutamate inhibitors, and cholinesterase inhibitors. Among the drug class the MAO inhibitors segment is expected to account for significant revenue share. The distribution channel is segmented into retail pharmacies, hospital pharmacies, and others. Among the distribution channel the retail pharmacies are expected to witness faster growth in the target market.

The players profiled in the report are Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., Valeant Pharmaceutical International, Eisai, Inc., Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.

Market Segmentation

Market By Drug Class

MAO Inhibitors

Glutamate Inhibitors

Cholinesterase Inhibitors

Market By Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Others

Market By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa


Frequently Asked Questions

The global dementia drugs market in 2027 is expected to be above US$ 24.7 Bn.

The CAGR of the global dementia drugs market from 2020-2027 is above 8.5%.

In distribution channel segment the retail pharmacies segment is growing at faster pace.

Increasing number of patients suffering from chronic diseases, high government spending on drug development and major players focus on introduction of innovative solutions are major factors expected to drive the growth of global market.

In the global market the Asia Pacific region is expected to grow faster.

Some of the players considered in the report scope are Valeant Pharmaceutical International, Eisai, Inc., Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.

The North America is expected to account for major revenue share in the global market.

Cart Summary


60